Complement-mediated inflammation of pulmonary alveolus in COVID-19 (hypothetical pathway) (WP5148)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
Hypothetical pathway for complement-mediated inflammation of the pulmonary alveolus in COVID-19. AEC‐II=Type II alveolar epithelial cell, EC=endothelial cells and MC=monocytes.

Authors

Susan Coort , Eric Weitz , Egon Willighagen , Nhung Pham , and Martina Summer-Kutmon

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Disease Ontology

COVID-19

Pathway Ontology

lectin complement pathway

Cell Type Ontology

epithelial cell of alveolus of lung

Participants
Query Drugst.One

Label Type Compact URI Comment
C6 GeneProduct ensembl:ENSG00000039537
C5b GeneProduct ensembl:ENSG00000106804
ACE2 GeneProduct ensembl:ENSG00000130234
MASP2 GeneProduct ensembl:ENSG00000009724
C7 GeneProduct ensembl:ENSG00000112936
C8 GeneProduct ncbigene:731
C3 GeneProduct ensembl:ENSG00000125730
C3AR1 GeneProduct ensembl:ENSG00000171860
C5 GeneProduct ensembl:ENSG00000106804
C5AR1 GeneProduct ensembl:ENSG00000197405
C9 GeneProduct ensembl:ENSG00000113600
Collectin-11 Protein uniprot:F8WB29
Ficolin-1 Protein uniprot:O00602

References

  1. Rationale for targeting complement in COVID-19. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, et al. EMBO Mol Med. 2020 Aug 7;12(8):e12642. PubMed Europe PMC Scholia